Credit Suisse’s stock is testing record lows, even as the Swiss bank is pulling in about $4.2 billion of new equity funding to shore up its finances.
Its shares fell nearly another 5% on Friday to as low as 3.37 Swiss francs, a new intraday nadir and set to be its lowest closing price on record.
T
Farallon has nominated three directors to the board of Exelixis, which develops cancer-fighting drugs.
Beijing is holding back its required green light for mergers that involve American companies as a technology war with Washington intensifies.
All those tech layoffs are starting to show up in employment statistics, but they still show little sign of spreading to other sectors.
